Be prepared for a lot more attention on the 340B program in the upcoming Congress, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.
340B was a hot topic in Congress
…
Year: 2022
Drug manufacturer Novo Nordisk for the third time this year has announced refunds for 340B overcharges due to revisions of Medicaid pricing data.
The U.S. Health Resources and Services Administration posted the company’s notice to covered entities on its website
…
California-based AIDS Healthcare Foundation (AHF) last week refiled its lawsuit against Delaware-based federally contracted 340B prime vendor Apexus, setting forth facts that AHF argued gives a federal district court in California jurisdiction over the case.
AHF, based in Los Angeles,
…
The Democratic vice chair of the U.S. House Energy & Commerce Committee said during a media event yesterday she hopes Congress will address healthcare providers’ concerns about the 340B program during its lame duck session scheduled to end Dec. 15.
…
Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.
“We found compelling evidence that
…
Novo Nordisk on Jan.1 will implement a policy to let 340B hospitals buy its drugs at a reduced 340B price for shipment to an unlimited number of contract pharmacies if the hospitals submit their claims data for such drugs to
…
340B hospital and pharmacy groups have launched another digital ad campaign touting the 340B program’s benefits to policymakers. It comes amid a rise in negative messages about 340B from the drug industry and conservative think tanks and the publication of
…
SPONSORED CONTENT
Join Verity Solutions for our next Lunch & Learn webinar session on Thursday, December 15 at 1:30PM ET as we welcome 340B Report Editor in Chief Tom Mirga for a discussion about new and ongoing 340B developments on the judicial, legislative, and regulatory fronts. Hear about current bills, the new Congress, and what it could mean for 340B.
Featured Speaker Tom Mirga, Editor in Chief, 340B Report
Tom Mirga is Editor In Chief of 340B Report with more than 40 years of experience in journalism and public affairs in Washington, D.C. He has focused exclusively on the 340B program since 2010.
Ryan White Clinics for 340B Access told a federal district judge last week it needs time to assess how proposed new 340B administrative dispute resolution regulations, if finalized, could affect the 340B overcharging claims it brought against AstraZeneca under the
…